<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01094041</url>
  </required_header>
  <id_info>
    <org_study_id>09-007344</org_study_id>
    <nct_id>NCT01094041</nct_id>
  </id_info>
  <brief_title>Gluten Intolerance in Patients With Diarrhea Predominant Irritable Bowel Syndrome</brief_title>
  <official_title>Gluten Intolerance in Irritable Bowel Syndrome With Diarrhea: The Role of HLA-DQ2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The specific hypotheses are:

      Gluten supplementation for four weeks increases small intestinal permeability and accelerates
      colonic transit in patients with irritable bowel syndrome with diarrhea (IBS-D) or functional
      diarrhea (FD) who are HLA-DQ2 positive.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study design is a double-blind, randomized, controlled, parallel-group, 6-week study
      comparing the effects of gluten rich versus gluten free diets in diarrhea or diarrhea
      predominant IBS patients. All participants will keep a daily bowel pattern diary throughout
      the study. All participants will have negative serum tissue transglutaminase (TTg) assay, and
      anti-endomysial antibody test, if TTg is positive or equivocal. All participants will have
      the following studies performed both before and after the 4-week dietary intervention:

        1. Stool samples to check markers of inflammation such as fecal calprotectin.

        2. Blood samples to check markers of inflammation and for genetic testing.

        3. After ingestion of the mannitol, lactulose and sucralose sugars, urine samples to
           indirectly measure small intestinal and colonic permeability.

        4. After sedation, upper gastrointestinal endoscopy and flexible sigmoidoscopy to obtain 6
           mucosal biopsies from the small bowel and sigmoid colon for immunohistochemical
           analysis.

        5. Scintigraphy to measure gastrointestinal transit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Small bowel permeability</measure>
    <time_frame>0 - 2 hours post sugar ingestion</time_frame>
    <description>Excretion of mannitol 0-2 hours after liquid formulation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Colonic permeability</measure>
    <time_frame>2 -24 hours post sugars ingestion</time_frame>
    <description>Cumulative excretion of mannitol at 2-24 hours after liquid</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Colonic transit</measure>
    <time_frame>24 hours</time_frame>
    <description>Colonic transit geometric center at 24 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Colon transit</measure>
    <time_frame>6-12 hours</time_frame>
    <description>Ascending colon emptying T1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Colonic permeability</measure>
    <time_frame>2-24 hours after sugars ingestion</time_frame>
    <description>Cumulative excretion of lactulose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Colonic permeability</measure>
    <time_frame>8 to 24 hours after ingestion of sugars</time_frame>
    <description>Hourly excretion of mannitol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Small bowel transit time</measure>
    <time_frame>6 hours</time_frame>
    <description>Colonic filling at 6 hours (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastric emptying</measure>
    <time_frame>0-2 hours</time_frame>
    <description>Gastric emptying T1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Colonic inflammatory response</measure>
    <time_frame>4 weeks</time_frame>
    <description>Sigmoid colon mucosal immunocyte count in lamina propria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool frequency and consistency</measure>
    <time_frame>6 weeks</time_frame>
    <description>Bowel pattern diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Small bowel inflammatory response</measure>
    <time_frame>4 weeks</time_frame>
    <description>Duodenal mucosal immunocyte count in lamina propria</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Diarrhea</condition>
  <condition>Diarrhea Predominant Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Gluten free diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Gluten rich diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Gluten free diet</intervention_name>
    <description>A 4-week gluten free diet provided</description>
    <arm_group_label>Gluten free diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Gluten rich diet</intervention_name>
    <description>A 4-week gluten rich diet is provided</description>
    <arm_group_label>Gluten rich diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Diarrhea or diarrhea predominant IBS patients

          2. Age 18 to 65

          3. BDQ confirms presence of IBS-D or functional diarrhea, positive by Rome III criteria

          4. No restrictions on Hospital Anxiety Depression score

          5. No abdominal surgery (except appendectomy and cholecystectomy)

        Exclusion criteria:

          1. Serum tissue transglutaminase IgA or IgG positive or medical record of small bowel
             biopsy suggestive of celiac disease

          2. Use of tobacco products within the past 6 months (since nicotine may affect intestinal
             permeability)

          3. Use of NSAIDs or aspirin within the past week (since NSAIDs affect intestinal
             permeability)

          4. Use of oral corticosteroids within the previous 6 weeks

          5. Ingestion of artificial sweeteners such as SplendaTM (sucralose), Nutrasweet
             TM(aspartame), lactulose or mannitol 2 days before the study begins, e.g., foods to be
             avoided are sugarless gums or mints and diet soda

          6. Ingestion of any prescription, over the counter, or herbal medications which can
             affect gastrointestinal transit 7 days before study begins.

          7. Any females who are pregnant or trying to become pregnant (due to radiation exposure)

          8. Bleeding disorders or medications that increase risk of bleeding from mucosal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Camilleri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2010</study_first_submitted>
  <study_first_submitted_qc>March 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2010</study_first_posted>
  <last_update_submitted>May 8, 2013</last_update_submitted>
  <last_update_submitted_qc>May 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2013</last_update_posted>
  <responsible_party>
    <name_title>Michael Camilleri, MD</name_title>
    <organization>Mayo Clinic</organization>
  </responsible_party>
  <keyword>Gluten</keyword>
  <keyword>Diarrhea or diarrhea predominant irritable bowel syndrome</keyword>
  <keyword>Colonic permeability</keyword>
  <keyword>Small bowel permeability</keyword>
  <keyword>Colonic inflammatory response</keyword>
  <keyword>Small bowel inflammatory response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Celiac Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

